Research & Development

Research

Mochida Pharmaceutical strives to provide medicines that correspond to patients ongoing requirements as quickly as we can.
We maximize foresight and originality in all processes, based on our unique research and development capabilities and diverse technological know-how cultivated over many years.
In order to make our pharmaceutical research even more efficient, we are enhancing development pipelines by introducing candidate drugs for development at an early stage by promoting “open innovation.”

Pipeline

As of July 31, 2017
Code Generic Name Indications Formulation Stage Remarks
LBEC0101 etanercept Rheumatoid arthritis Injection Filed Biosimilar
Licensed-in from LG Chem
[Korea]
AJG533 elobixibat Chronic constipation Oral Filed Co-development with EA Pharma
[Japan]
LBAL adalimumab Rheumatoid arthritis Injection Phase Ⅲ Biosimilar
Licensed-in from LG Chem
[Korea]
RGB-10 teriparatide Osteoporosis Injection Phase Ⅲ Biosimilar
Licensed-in from Gedeon Richter
[Hungary]
FYU-981

Gout and hyperuricemia Oral Phase Ⅲ Co-development with Fuji yakuhin
[Japan]
MJR-35 dienogest Dysmenorrhea Oral Phase Ⅲ Licensed-in from Jenapharm (a subsidiary of Bayer AG)
[Germany]
MD-711 treprostinil Pulmonary arterial hypertension Inhalant Preparation for Phase Ⅰ Licensed-in from United Therapeutics
[USA]
[Medical device]
dMD-001 sodium alginate Articular cartilage lesion   Therapeutic exploratory study (Pilot study)